Saar I. Gill

Saar I. Gill, MD, PhD is a Professor of Medicine in the Hematology-Oncology Division at the Hospital of the University of Pennsylvania and serves as Scientific Co-Director of the Cell Therapy and Transplant Program at the Abramson Cancer Center. He maintains an active clinical practice at the Perelman Center for Advanced Medicine, specializing in cellular immunotherapies for hematologic malignancies.

Education:

• Medical Degree: University of Melbourne
• Residency: St. Vincent's Hospital Melbourne
• Fellowship: Peter MacCallum Cancer Centre
• Fellowship: Hospital of the University of Pennsylvania

Dr. Gill's research program centers on advancing cellular immunotherapies, with recent focus on CAR T-cell and CAR macrophage engineering for hematologic and solid tumors. His work integrates basic science investigations into gene editing safety mechanisms with clinical translation, including leadership in developing international consensus guidelines for CAR T-cell trials in AML. Current projects address critical challenges in the field such as solid tumor resistance to immunotherapy, transplant complications like bronchiolitis obliterans, and health equity in cancer outcomes.

Scientific Recognition: While specific awards aren't detailed, Dr. Gill's patient satisfaction score of 4.8/5 (50 reviews) highlights exceptional clinical rapport, with patients consistently praising his expertise and compassionate care approach. His publication record in premier journals including Nature Medicine and Blood Advances demonstrates field leadership.

As Scientific Co-Director of the Cell Therapy and Transplant Program, Dr. Gill oversees a multidisciplinary team developing next-generation cellular therapies. His active clinical trial portfolio includes phase 1 studies of CAR-macrophage therapies for solid tumors and initiatives to improve access to advanced immunotherapies across diverse patient populations.

The Cell Therapy and Transplant Program under Dr. Gill's co-direction represents a major hub for cellular therapy innovation at Penn Medicine, integrating laboratory research with clinical delivery of cutting-edge treatments including CAR T-cell therapies and hematopoietic stem cell transplantation for complex hematologic malignancies.